-
New Biomarker ‘Bim’ Could Enable Smarter Treatment for Melanoma Patients
Over the past few years, checkpoint blockade immunotherapies have revolutionized cancer treatment and helped many patients who…
-
Third Immunotherapy Option Approved for Bladder Cancer Patients
On February 2, nivolumab (Opdivo®, Bristol-Myers Squibb) became the newest FDA-approved immunotherapy available for patients with bladder…
-
Immunotherapy Shows Promise Against Previously Untreatable Stomach Cancer
Nivolumab improves survival in patients with advanced stomach cancer.
-
2016: The Year of Cancer Immunotherapy
New immunotherapy approvals, “Advance of the Year” recognition, and the partnerships of the future.
-
Immuno-Oncology 360°: Connecting Science & Business to Advance Immunotherapy
The third annual IO360° conferences comes to NYC February 2017.
-
Remembering Renowned Immunology Pioneer Georg Klein
The longtime member of CRI’s Scientific Advisory Council sought to save lives through research and education.
-
ASH 2016: Tackling Blood Cancers with Immunotherapy
The largest meeting focused on blood cancers begins December 3 in San Diego.
-
CRI, LRF Team Up to Improve How Doctors Assess Lymphoma Patients Treated with Immunotherapy
LYRIC might provide a better way to gauge immunotherapy responses in lymphoma patients. Clinical trials are essential…
-
CNN Highlights Cancer Immunotherapy Advances, CRI’s Pioneering Role
First-line lung cancer immunotherapy approval results from century-long effort to harness the immune system to fight cancer.
